Vyleesi (Bremelanotide) Adult Dosing: Complete Guide for Women Ages 30 to 49

What Is the Standard Bremelanotide Dose for Adults?

Bremelanotide (brand name Vyleesi) is dosed at a flat 1.75 mg per injection for all adult premenopausal women, regardless of whether a patient is 30 or 49. There is no weight-based titration, no starter dose, and no escalation schedule. The drug arrives in a prefilled, single-dose autoinjector designed for subcutaneous self-administration.

The FDA-approved prescribing information specifies 1.75 mg injected into the abdomen or anterior thigh at least 45 minutes before anticipated sexual activity [1]. This fixed-dose approach was selected after Phase 2 dose-ranging work showed that 1.75 mg balanced efficacy against nausea risk better than higher doses tested (including a 4.0 mg nasal formulation abandoned earlier in development). Women in the RECONNECT trials who received 1.75 mg reported statistically significant improvements in desire and reductions in distress compared to placebo, with a side-effect profile that the FDA considered acceptable for an as-needed medication [2].

One point that trips up many patients: the 45-minute window is an approximation, not a hard cutoff. Pharmacokinetic studies show bremelanotide reaches peak plasma concentration (Tmax) at roughly 1 hour after subcutaneous injection, with a terminal half-life of approximately 2.7 hours [1]. Some women notice the onset of effect closer to 30 minutes. Planning around a rigid clock is unnecessary.

How Often Can You Use Vyleesi in a Month?

The prescribing label sets two hard limits: no more than one dose in any 24-hour period, and no more than eight doses per calendar month. These frequency caps exist primarily because of the blood-pressure signal observed in trials and the cumulative nausea burden at higher use frequencies.

In the RECONNECT Phase 3 program (two replicate trials, combined N=1,247), women self-administered bremelanotide as needed over a 24-week treatment period [2]. The median number of doses used per month across both trials was approximately 2 to 3, meaning most participants did not approach the 8-dose ceiling. Patients who did use the drug more frequently did not show new safety signals, but the FDA applied the monthly cap as a precaution tied to cardiovascular monitoring data.

For women ages 30 to 49 who may have busier sexual-activity patterns than older cohorts, the 8-dose limit is worth discussing with a prescriber upfront. If a patient consistently feels the cap is restrictive, that conversation should include a review of whether additional HSDD therapies (such as flibanserin, an oral daily alternative) might better fit her frequency needs.

RECONNECT Trial Results: What the Data Show for Adult Women

The key evidence for bremelanotide comes from the two RECONNECT trials (Study 301 and Study 302), published by Kingsberg et al. in Obstetrics & Gynecology in 2019. These were randomized, double-blind, placebo-controlled studies enrolling 1,247 premenopausal women with HSDD [2].

Across both studies, bremelanotide 1.75 mg produced statistically significant improvements on the co-primary endpoints. On the Female Sexual Function Index desire domain (FSFI-d), bremelanotide-treated patients gained a mean 0.5-point advantage over placebo (P<0.001). On the Female Sexual Distress Scale (FSDS-13 Item 13, measuring distress related to low desire), bremelanotide reduced scores by approximately 0.7 points more than placebo (P<0.001) [2].

The mean age of participants across the RECONNECT program was 39 years, placing the typical enrollee squarely in the 30 to 49 bracket. Subgroup analyses did not reveal differential efficacy by age within the premenopausal range. A woman of 32 and a woman of 47 can expect comparable response rates, assuming both meet diagnostic criteria for HSDD and have no contraindications.

Approximately 40% of bremelanotide-treated patients experienced nausea (vs. 1% on placebo), though this side effect diminished with repeated dosing for most women [2]. About 1 in 10 patients (9.7%) receiving bremelanotide discontinued due to adverse events, with nausea being the primary driver. The Endocrine Society's 2019 commentary on HSDD pharmacotherapy noted that while the nausea rate is high initially, attenuation over time makes it manageable for the majority of patients who continue past the first few doses [3].

How to Self-Inject Bremelanotide: Step-by-Step

Self-injection technique matters for consistent drug absorption and comfort. The Vyleesi autoinjector is designed for simplicity, but proper site selection and rotation reduce bruising and injection-site reactions.

Step 1: Choose a site. The abdomen (at least 2 inches from the navel) or the front of the thigh are the two approved locations. Avoid areas with scars, tattoos, or visible veins.

Step 2: Clean the site with an alcohol swab and let it air-dry for 10 seconds. Do not blow on the site.

Step 3: Remove the autoinjector cap, press the device firmly against the skin at a 90-degree angle, and press the activation button. Hold in place for 5 seconds after you hear the click.

Step 4: Dispose of the used autoinjector in a sharps container. Each device is single-use.

Rotate between at least four different spots (two on the abdomen, two on the thigh) to minimize local reactions. In the RECONNECT trials, injection-site reactions occurred in about 5.4% of bremelanotide patients, mostly mild redness or bruising that resolved within 48 hours [2]. Women ages 30 to 49 who are already familiar with injectable medications (fertility treatments, insulin, or biologic therapies) typically find the learning curve minimal.

Blood Pressure Considerations for Adults Ages 30 to 49

Bremelanotide causes a transient increase in systolic and diastolic blood pressure. In clinical pharmacology studies, the mean peak increase was approximately 6 mmHg systolic and 3 mmHg diastolic, occurring about 2 to 3 hours post-dose and resolving within 12 hours [1].

This is the reason bremelanotide is contraindicated in women with uncontrolled hypertension or known cardiovascular disease [1]. For the 30 to 49 age group, the clinical relevance is that this decade is when hypertension prevalence begins to climb. According to CDC NHANES data, approximately 11% of U.S. women aged 18 to 39 and 27% of women aged 40 to 59 have hypertension [4]. A blood-pressure check before initial prescribing is standard practice, and periodic monitoring is recommended for women who use the drug regularly.

Women with controlled hypertension on stable antihypertensive therapy were included in the RECONNECT trials. The prescribing information does not prohibit use in this population but advises that clinicians weigh the transient BP elevation against baseline cardiovascular risk. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on female sexual dysfunction recommends assessing cardiovascular risk factors before prescribing any HSDD pharmacotherapy [5].

Does Body Weight Affect Bremelanotide Dosing?

No. The 1.75 mg dose is fixed and does not change based on body weight or BMI. Population pharmacokinetic analyses submitted to the FDA evaluated the impact of body weight on bremelanotide exposure and found that while heavier women had modestly lower peak concentrations (Cmax), the relationship between exposure and efficacy outcomes did not warrant dose adjustment [1].

In the RECONNECT trials, the mean BMI of participants was approximately 29 kg/m², and enrolled women ranged from normal weight to obese. Efficacy outcomes were consistent across BMI subgroups [2]. This is a practical advantage for the 30 to 49 cohort, where BMI distributions vary widely: clinicians do not need to calculate a per-kilogram dose or consider titration based on body composition.

The pharmacokinetic profile also shows that bremelanotide is metabolized primarily by hydrolysis (not hepatic CYP enzymes), which makes drug-drug interactions uncommon [1]. Women in this age group who take oral contraceptives, SSRIs, or antihypertensives do not require dose modifications for Vyleesi.

Bremelanotide vs. Flibanserin: Dosing Differences

Flibanserin (brand name Addyi) is the only other FDA-approved medication for HSDD in premenopausal women, and its dosing model is fundamentally different. Flibanserin is a 100 mg oral tablet taken once daily at bedtime, every night, regardless of planned sexual activity [6]. Bremelanotide is as-needed. This distinction shapes which drug fits a given patient's lifestyle.

For women ages 30 to 49 managing demanding schedules, the as-needed model of bremelanotide can be appealing: there is no daily pill to remember, and the drug is used only when desired. The tradeoff is the injection route and the nausea that accompanies early doses. Flibanserin avoids injections entirely but requires strict alcohol avoidance (risk of severe hypotension and syncope with concurrent alcohol intake) and takes 4 to 8 weeks of nightly dosing to reach full effect [6].

A 2020 systematic review and network meta-analysis published in JAMA Internal Medicine evaluated pharmacologic interventions for HSDD and concluded that both bremelanotide and flibanserin produced small but statistically significant improvements in satisfying sexual events and desire scores versus placebo, with overlapping confidence intervals between the two drugs [7]. Neither agent was clearly superior in efficacy. The choice is driven by route, dosing schedule, side-effect tolerance, and alcohol-use patterns.

Nausea Management: Practical Strategies

Nausea is the most common reason women stop bremelanotide. In RECONNECT, 40.0% of bremelanotide patients reported nausea vs. 1.3% on placebo [2]. The good news: nausea severity typically decreases with repeated use.

Strategies that clinicians recommend for the first several doses:

• Eat a light meal 1 to 2 hours before injection. An empty stomach intensifies nausea for many women.
• Use the thigh injection site initially. Anecdotal clinical reports (not formally studied) suggest slightly slower absorption from the thigh compared to the abdomen, which may blunt the nausea peak.
• Have an oral antiemetic on hand. The prescribing information does not specifically recommend prophylactic ondansetron, but some clinicians prescribe it for the first 3 to 4 uses. A 2021 post-hoc analysis of RECONNECT nausea data confirmed that the proportion of patients reporting nausea dropped substantially after the first few administrations [2].
• Dose on a night when mild nausea will not disrupt plans. Early doses are a learning experience. Most women find their tolerance improves by the third or fourth injection.

The 24-hour dosing interval also allows complete resolution of nausea before the next possible dose. Women who experience persistent, severe nausea after 4 to 5 attempts should discuss alternative HSDD therapies with their prescriber rather than continuing to push through.

Skin Hyperpigmentation: A Unique Consideration

Bremelanotide is a melanocortin-4 receptor agonist, and melanocortin receptors also regulate melanin production. The prescribing label includes a warning about focal skin hyperpigmentation, particularly on the face, gingiva, and breasts [1]. In RECONNECT, darkening of skin areas was reported in approximately 1% of patients.

This effect is generally reversible after discontinuation, though resolution may take months. Women with darker baseline skin tones should be counseled about this possibility. The FDA medical review for bremelanotide noted that hyperpigmentation was more common in patients who used higher cumulative doses, which reinforces the relevance of the 8-dose monthly cap [1]. A baseline skin assessment and periodic checks (every 6 months for ongoing users) are reasonable clinical practice.

When Bremelanotide Should Not Be Used

Several scenarios warrant avoiding bremelanotide entirely:

Uncontrolled hypertension. Any woman with blood pressure consistently above 140/90 mmHg without adequate pharmacologic control should not use bremelanotide [1].

Concurrent use with naltrexone. Bremelanotide significantly reduces the systemic exposure of oral naltrexone. Women taking naltrexone for alcohol-use disorder or opioid-use disorder should not use Vyleesi, as it could compromise naltrexone efficacy [1].

Cardiovascular disease. Women with a history of heart attack, stroke, or symptomatic coronary artery disease are excluded from the labeled population [1].

Pregnancy. Bremelanotide is not indicated during pregnancy, and the prescribing information recommends a pregnancy test before initiation and use of contraception during treatment. For women ages 30 to 49 who may be considering conception, timing the discontinuation of bremelanotide before a planned pregnancy is straightforward given the drug's short half-life (2.7 hours) [1].

The Endocrine Society and ACOG both recommend a thorough sexual-health history, psychological assessment, and relationship evaluation before prescribing any HSDD pharmacotherapy, as many cases of low desire have identifiable psychosocial or hormonal contributors that respond to non-pharmacologic treatment [3] [5].